CNSX:PHRM

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

PharmaTher Inc., pharmaceutical company, engages in repurposing psychedelic-derived drugs using artificial intelligence platform. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Newscope Capital's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PHRM is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 68% a week.

Volatility Over Time: Insufficient data to determine PHRM's volatility change over the past year.


Market Performance


7 Day Return

88.5%

PHRM

7.8%

CA Pharmaceuticals

2.5%

CA Market


1 Year Return

n/a

PHRM

13.1%

CA Pharmaceuticals

-0.5%

CA Market

Return vs Industry: Insufficient data to determine how PHRM performed against the Canadian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how PHRM performed against the Canadian Market.


Shareholder returns

PHRMIndustryMarket
7 Day88.5%7.8%2.5%
30 Day58.1%29.1%9.3%
90 Dayn/a32.7%5.6%
1 Yearn/a13.1%13.1%3.1%-0.5%
3 Yearn/a-28.5%-29.7%12.8%1.9%
5 Yearn/a256.1%253.0%47.5%24.9%

Long-Term Price Volatility Vs. Market

How volatile is Newscope Capital's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Newscope Capital undervalued compared to its fair value and its price relative to the market?

22.13x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PHRM's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PHRM's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: Insufficient data to calculate PHRM's PE Ratio to determine if it is good value compared to the CA Pharmaceuticals industry average.

PE vs Market: Insufficient data to calculate PHRM's PE Ratio to determine if it is good value compared to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PHRM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PHRM is overvalued based on its PB Ratio (19.4x) compared to the CA Pharmaceuticals industry average (1.5x).


Next Steps

Future Growth

How is Newscope Capital forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

59.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Newscope Capital has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Newscope Capital performed over the past 5 years?

5.2%

Historical Pharmaceuticals & Biotech annual earnings growth


Earnings and Revenue History

Quality Earnings: PHRM is currently unprofitable.

Growing Profit Margin: PHRM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if PHRM's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare PHRM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PHRM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-45%).


Return on Equity

High ROE: PHRM has a negative Return on Equity (-37.64%), as it is currently unprofitable.


Next Steps

Financial Health

How is Newscope Capital's financial position?


Financial Position Analysis

Short Term Liabilities: PHRM's short term assets (CA$390.4K) exceed its short term liabilities (CA$10.7K).

Long Term Liabilities: PHRM has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: PHRM is debt free.

Reducing Debt: PHRM has not had any debt for past 5 years.

Debt Coverage: PHRM has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: PHRM has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Newscope Capital current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PHRM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PHRM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PHRM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PHRM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PHRM's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Fabio Chianelli (42 yo)

no data

Tenure

Mr. Fabio Chianelli is the Founder of Newscope Capital Corporation (formerly known as PharmaTher Inc.). and serves as its CEO & Director. He had been the President of Revive Therapeutics Ltd. since July 20...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: PHRM only recently listed within the past 12 months.


Top Shareholders

Company Information

Newscope Capital Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Newscope Capital Corporation
  • Ticker: PHRM
  • Exchange: CNSX
  • Founded: 2020
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$10.339m
  • Shares outstanding: 48.09m

Location

  • Newscope Capital Corporation
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PHRMCNSX (Canadian National Stock Exchange)YesCommon SharesCACADOct 2020
PHRR.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDOct 2020

Biography

PharmaTher Inc., pharmaceutical company, engages in repurposing psychedelic-derived drugs using artificial intelligence platform. The company was incorporated in 2020 and is based in Toronto, Canada.


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/27 00:44
End of Day Share Price2020/11/26 00:00
Earnings2020/05/31
Annual Earnings2020/05/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.